---
title: Rounding Out National Cancer Research Month
description: Research reveals genetic similarities between canine and human cancers The biomarkers validate targeted therapies how dogs serve a model for human oncology
image: https://blog.fidocure.com/hubfs/Cancer%20Type%20Blog%20Sized%20%20(1).png
---
[](https://www.fidocure.com/)
- [Veterinarians](https://fidocure.com/for-veterinarians/)
- [Portal Login](https://dvm.fidocure.com/)
- [Veterinary Blog](https://blog.fidocure.com/fidocure-blog/tag/vet)
- [Case Studies](https://blog.fidocure.com/fidocure-blog/tag/case-studies)
- [Webinars](https://blog.fidocure.com/fidocure-blog/tag/webinars)
- [Pet Parents](https://fidocure.com/pet-parents/)
- [About Us](https://fidocure.com/about-us/)
- [How it works](https://fidocure.com/how-it-works/)
- [Find a Clinic](https://fidocure.com/find-a-clinic/)
- [Contact Us](https://fidocure.com/contact-us/)
# Rounding Out National Cancer Research Month
[FidoCure](https://blog.fidocure.com/fidocure-blog/author/fidocure)
[Share this blog post on Twitter](https://twitter.com/intent/tweet?text=I+found+this+interesting+blog+post&url=https://blog.fidocure.com/fidocure-blog/rounding-out-national-cancer-research-month) [Share this blog post on Facebook](http://www.facebook.com/share.php?u=https://blog.fidocure.com/fidocure-blog/rounding-out-national-cancer-research-month) [Share this blog post on LinkedIn](http://www.linkedin.com/shareArticle?mini=true&url=https://blog.fidocure.com/fidocure-blog/rounding-out-national-cancer-research-month)
As we round out National Cancer Research Month, we want to highlight the important work being done by FidoCure researchers in comparative oncology. At FidoCure, we’ve pioneered canine cancer research backed by real-world evidence and published our findings in 4 of the most prestigious peer-reviewed scientific journals. Many of these papers are go-to sources for groundbreaking discoveries and advancements in cancer research. Our studies, led by FidoCure’s Head of Veterinary Research, Dr. Lucas Rodrigues, DVM, MS, PhD, have shed light on the similarities between canine and human cancers, paving the way for novel treatment approaches that could benefit both humans and dogs alike. Below, you can find the key points of Fidocure’s Nature, Precision Oncology, Elsevier and Veterinary & Comparative Oncology scientific papers.
NPJ Precision Oncology - *Analyses of canine cancer mutations and treatment outcomes using real-world clinico-genomics data of 2119 dogs*
1. The study analyzed genetic mutations, tumor types, and treatment outcomes for 2119 dogs with spontaneous tumors enrolled in the FidoCure Precision Medicine Platform. Mutations in 48 genes commonly mutated in human cancers were evaluated.
2. Mutations in TP53 and PIK3CA were associated with worse prognosis in the dogs, while mutations in NRAS, ATM, and KIT were associated with better prognosis. These findings showed concordance with human studies for TP53, ATM and KIT mutations.
3. Several targeted therapies designed for humans were associated with positive outcomes when used to treat canine tumors with specific genomic alterations. For example, lapatinib had a positive effect for tumors with BRAF mutations, and trametinib for those with ARID1A mutations.
4. The spontaneous canine tumor model provides a valuable opportunity to identify biomarkers associated with prognosis and treatment response to inform drug development for human precision oncology. The overlap of canine and human cancer mutations associated with therapeutic response can help advance novel treatment strategies.
Nature - *Shared hotspot mutations in oncogenes position dogs as an unparalleled comparative model for precision therapeutics*
1. This study used targeted sequencing of 56 cancer-associated genes in 109 dogs with splenic hemangiosarcoma (HSA) to identify somatic mutations and germline variants associated with clinical features and outcomes. HSA is an aggressive cancer with poor prognosis in dogs and is a relevant comparative model for human angiosarcoma.
2. The most commonly mutated genes were TP53 (41% of cases), NRAS (18%), and PIK3CA (17%). These frequencies are similar to previous canine HSA studies and human angiosarcoma. Certain mutation patterns suggested convergent effects on key signaling pathways.
3. Survival analysis found that presence of metastasis at diagnosis and germline variants in SETD2 and NOTCH1 were associated with significantly shorter overall survival times. SETD2 variants have been previously linked to cancer progression and poor prognosis in several human cancers.
4. Breed-specific differences were noted, with German Shepherd dogs diagnosed at a younger age and carrying germline CDKN2A variants more frequently than Golden Retrievers and Labrador Retrievers. TP53 and PIK3CA mutations were more common in larger breed dogs.
Elsevier - *Precision Medicine in Veterinary Science*
1. Precision medicine uses an individual's genomic information to guide prevention, diagnosis, prognosis and treatment of disease. The success of precision medicine in human oncology, based on understanding cancer's genomic heterogeneity and pairing targeted therapies with specific mutations, paves the way for similar approaches in veterinary medicine.
2. Genomic studies have identified mutations and molecular pathways driving canine cancers that are similar to human cancers. This enables translation of knowledge and therapeutic strategies from human to veterinary oncology. Multiple genomic assays for diagnosis, prognosis, treatment selection and monitoring are now commercially available for dogs.
3. Targeted therapies designed for human cancers, such as small molecule inhibitors, are being used in dogs with specific genomic alterations. Early studies show promise for genomically-guided targeted therapies, alone or combined with conventional treatments, in improving outcomes for canine cancer patients.
4. Precision medicine can be integrated into veterinary oncology practice at multiple points, including using genomic assays for ambiguous diagnoses, prognostication, treatment selection, early cancer screening, and monitoring. As costs decrease, utilization of precision medicine in dogs is expected to expand, improving the knowledge base for clinical decision-making.
Veterinary and Comparative Oncology -*Precision Medicine Tools Offer Veterinarians New Hope for Understanding Hemangiosarcoma*
1. This study used targeted sequencing of 56 cancer-associated genes in 109 dogs with splenic hemangiosarcoma (HSA) to identify somatic mutations and germline variants associated with clinical features and outcomes. HSA is an aggressive cancer with poor prognosis in dogs and is a relevant comparative model for human angiosarcoma.
2. The most commonly mutated genes were TP53 (41% of cases), NRAS (18%), and PIK3CA (17%). These frequencies are similar to previous canine HSA studies and human angiosarcoma. Certain mutation patterns suggested convergent effects on key signaling pathways.
3. Survival analysis found that presence of metastasis at diagnosis and germline variants in SETD2 and NOTCH1 were associated with significantly shorter overall survival times. SETD2 variants have been previously linked to cancer progression and poor prognosis in several human cancers.
4. Breed-specific differences were noted, with German Shepherd dogs diagnosed at a younger age and carrying germline CDKN2A variants more frequently than Golden Retrievers and Labrador Retrievers. TP53 and PIK3CA mutations were more common in larger breed dogs.
In summary, the remarkable progress being made in comparative oncology highlights the importance of collaboration between veterinary and human medicine, as we work together to combat cancer on all fronts. We look forward to continuing our dedication to cancer research on both ends of the leash.
## Related Articles
[.jpg)](https://blog.fidocure.com/fidocure-blog/how-fidocure-research-is-rewriting-the-rules-for-dogs-with-hemangiosarcoma)
### [How FidoCure Research is Rewriting the Rules for Dogs with Hemangiosarcoma](https://blog.fidocure.com/fidocure-blog/how-fidocure-research-is-rewriting-the-rules-for-dogs-with-hemangiosarcoma)
Pet parents who hear the devastating diagnosis of hemangiosarcoma (HSA) in their beloved dogs face a grim timeline and limited options. Known as one of the deadliest...
[FidoCure](https://blog.fidocure.com/fidocure-blog/author/fidocure)
[Read More](https://blog.fidocure.com/fidocure-blog/how-fidocure-research-is-rewriting-the-rules-for-dogs-with-hemangiosarcoma)
[](https://blog.fidocure.com/fidocure-blog/research-featured-in-the-cancer-letter)
### [Research featured in The Cancer Letter](https://blog.fidocure.com/fidocure-blog/research-featured-in-the-cancer-letter)
We were thrilled to see our recent Nature paper featured in last week's issue of***[The Cancer Letter](https://fidocu.re/cancerletter)***! Our multi-year study has compared canine and human cancer journeys...
[Christina K. Lopes](https://blog.fidocure.com/fidocure-blog/author/christina-k-lopes)
[Read More](https://blog.fidocure.com/fidocure-blog/research-featured-in-the-cancer-letter)
- [How it Works](https://fidocure.com/how-it-works/)
- [FAQ](https://fidocure.com/faq/)
- [Contact Us](https://fidocurestg.wpengine.com/contact-us/)
- [For Vets](https://fidocure.com/for-veterinarians/)
- [About Us](https://fidocure.com/about-us/)
- [Terms of Service](https://fidocure.com/terms-of-service/)
- [Blog](https://blog.fidocure.com/fidocure-blog)
- [Careers](https://fidocure.com/careers/)
- [Privacy Policy](https://fidocure.com/privacy-policy/)
-
-
-
-
**FidoCure® is an advanced cancer-care service for dogs, developed by One Health Company**. DISCLAIMER: All patients are enrolled in FidoCure® by a veterinarian with a valid veterinarian-client-patient relationship (VCPR). We use best efforts to inform the veterinarian on available targeted therapy options for patients. FidoCure® does not prescribe therapy. The targeted therapies that veterinarians may prescribe and order from compounding pharmacies, after receiving genetic test results from FidoCure®, may constitute extra-label uses of those drugs. FidoCure® makes no claims that every patient will have genetic test results that lead to targeted therapy options. FidoCure® makes no claims or guarantees about the effectiveness of the diagnostic and targeted therapy selected by the veterinarian for an individual patient. Like most cancer care approaches, the services provided by FidoCure® are not a guarantee of a cure. FidoCure® is not a pharmacy and does not supply drugs directly. By ordering any medication via one of our pharmacy partners, you agree that the pharmacy, not FidoCure®, is solely responsible and liable for any and all issues relating to the preparation, dispensation and fulfillment of the medication. The lifetime offer is subject to the commercially reasonable availability of any medication(s) and/or active pharmaceutical ingredient(s) necessary for the selected therapy.
© Copyright 2018-2026 One Health Company, All rights reserved
```json
{
"@context" : "https://schema.org",
"@type" : "BlogPosting",
"author" : {
"@type" : "Person",
"name" : "FidoCure",
"url" : "https://blog.fidocure.com/fidocure-blog/author/fidocure"
},
"dateModified" : "2024-05-31T16:35:32.118Z",
"datePublished" : "2024-05-31T16:00:00.000Z",
"headline" : "Rounding Out National Cancer Research Month",
"image" : [ "https://blog.fidocure.com/hubfs/Cancer%20Type%20Blog%20Sized%20%20(1).png" ],
"mainEntityOfPage" : {
"@id" : "https://blog.fidocure.com/fidocure-blog/rounding-out-national-cancer-research-month",
"@type" : "WebPage"
},
"publisher" : {
"@type" : "Organization",
"logo" : {
"@type" : "ImageObject",
"url" : "https://blog.fidocure.com/hubfs/fidocure_logo.png"
},
"name" : "FidoCure"
}
}
```